Fred Hutch has been at the forefront of developing transplantation for aplastic anemia since the 1970s. Over the following decades, advances in donor matching, chemotherapy regimens, and prevention of graft-versus-host disease (GVHD) have dramatically improved patient outcomes.
A previous study examined Fred Hutch's experience treating patients with aplastic anemia over six decades. Among patients receiving transplants from matched related donors, one-year survival increased from 56% in the 1970s to nearly 100% among those transplanted after 2010.
Finding a suitable stem cell donor was once one of the biggest hurdles. Historically, a matched sibling was the preferred donor, leaving patients without one facing more limited treatment choices. Improvements in transplantation techniques and GVHD prevention have since expanded the use of unrelated and partially matched donors, increasing access to this potentially lifesaving treatment.
While these advances have improved survival, considerably less is known about how patients fare decades after treatment. "Most of the guidelines that we have come from transplants for malignant diseases," explained Dr. Bhatt, a pediatric transplant physician whose research focuses on long-term health outcomes following transplantation for nonmalignant (non-cancerous) diseases. Although many of the treatments are similar, patients undergoing transplantation for non-cancerous conditions, such as aplastic anemia, may face different long-term health challenges than those treated for cancer. And as transplantation practices continue to evolve, understanding whether donor type influences these outcomes has become increasingly important.
To investigate these questions, the researchers turned to a unique resource: Fred Hutch's Long-Term Follow-Up Program. Every year, participating transplant survivors receive questionnaires asking about their health, medications, education, employment, and quality of life. Some patients who received transplants in the 1970s continue to complete these surveys more than four decades later, providing what Bhatt described as a "treasure trove of information" about life after transplantation.
For the new study, the team analyzed survey responses from 122 patients who underwent transplantation for severe aplastic anemia at Fred Hutch between 1972 and 2021. With a median of 26 years between transplantation and survey completion, the responses offered a long-term perspective on survivorship.
The researchers examined participants' self-reported chronic health conditions, medication use, and physical and mental quality of life. They also compared outcomes across three donor groups: matched related donors, matched unrelated donors, and alternative donors.
The results were encouraging. Among the 96 participants who completed quality-of-life assessments, average physical and mental health scores were comparable to those of the general population. Nearly three-quarters of participants of working age also reported being employed full-time or part-time. Quality-of-life scores were also broadly similar across donor groups, suggesting that patients receiving transplants from unrelated or alternative donors can also experience favorable long-term outcomes.
For Bhatt, these findings were reassuring, particularly given the intensive treatments many patients had undergone decades earlier.
However, surviving transplantation was not without its challenges. Many participants continued to experience chronic health conditions. Sexual dysfunction was the most frequently reported condition, affecting 35% of adult respondents, while cataracts and reduced bone mineral density were each reported by approximately 20% of participants. Patients who received alternative donor transplants were also more likely to report musculoskeletal complications than those who received matched related donor transplants.
Nevertheless, the findings provide valuable insight into the lives of patients who underwent transplantation decades ago and offer an important starting point for understanding the long-term consequences of different treatment approaches.
Looking ahead, Dr. Bhatt hopes to investigate the long-term effects of newer treatment strategies, particularly the use of targeted regimens like post-transplant cyclophosphamide to prevent GVHD. This approach has helped expand the use of partially matched donors, but questions remain about its effects on fertility, organ function, and other aspects of long-term health. The study also reinforces the importance of lifelong follow-up care. Some complications may emerge decades after transplantation, making continued monitoring essential for identifying and managing health problems as they arise.
Ultimately, Dr. Bhatt sees successful treatment as more than simply curing aplastic anemia. In his clinical practice, he wants to know whether patients are participating in the activities they had envisioned before their diagnosis. Decades of advances in transplantation have transformed the outlook for patients with severe aplastic anemia. Now, as more patients live longer after treatment, ensuring they can enjoy those additional years is becoming an equally important measure of success.